View Update Series
View CME info
View all audits
View all discussions
please login to access my bpac
Dont have an account? Sign up here
Forgot your login? Reset password
For more than 50 years, people with asthma have been prescribed a short-acting beta2-agonist (SABA) as the first-line treatment for symptom relief. However, the accumulated weight of evidence has shifted and regular use of a SABA without concurrent inhaled corticosteroid (ICS) is no longer recommended for adolescents or adults.
Published: 4 August 2020
Log in if you are a prescriber, to see your personalised and practice prescribing data.
Click here if you are not a prescriber, to see the national report version.
We have now added the ability to add replies to a comment. Simply click the "Reply to comment" button and complete the form.
Your reply, once signed off, will appear below the comment to which you replied
(if multiple replies to a comment, they will appear in order of submission)
You can still add a fresh comment by scrolling to the bottom of the discussion and clicking the "Add a comment" button.
If someone adds a reply to one of your comments (or replies) you will recieve an email notifying you of this. You can opt out of
(or into if currently out) all comment notification emails by clicking the button below
Please login to make a comment.
Made with by the bpacnz team